May 20th, 2:30 PM

Optimizing the Exercise Drug to Oppose Glucose Intolerance/T2D

Barry Braun
University of Massachusetts Amherst, bbraun@kin.umass.edu

Follow this and additional works at: http://escholarship.umassmed.edu/cts_retreat
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Endocrinology, Diabetes, and Metabolism Commons, Exercise Science Commons, Nutritional and Metabolic Diseases Commons, and the Translational Medical Research Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
Optimizing the Exercise Drug to Oppose Glucose Intolerance/T2D

Barry Braun, PhD
Dept. of Kinesiology
University of Massachusetts Amherst
Lab mission: Metabolic rehabilitation

Understand how physical activity, diet and pharmacology can be optimally integrated to reverse insulin resistance and prevent T2D
79 million with prediabetes =

everyone in U.S. that is left-handed (30) +
everyone who is Jewish (6) +
all households in U.S. that own dogs (43).

Insulin resistance is an underlying theme for Type-2 diabetes (as well as CVD)
Insulin Resistance
Diabetes Prevention Program, NEJM, 2001

>150’ exercise/wk. goal to lose 7% BW.
Lifestyle change

Weight loss

beneficial impact on metabolic health

Metformin
Mean weight loss: 3.3 kg

Activity maintained at about 150’/wk
Lifestyle change

Weight loss

beneficial impact on metabolic health

habitual activity

Metformin
Single dose

King et al., JAP, 1995

**Insulin Area (μU·ml⁻¹·min⁻¹)**

- **IPE**
- 1
- 3
- 5
- 7

* Sign indicates significance.
Lifestyle change

Weight loss

exercise training

acute exercise

Metformin

beneficial impact on metabolic health
Exercise as drug

At sufficient dose, exercise improves metabolic function for a period of time but the effect wanes, requiring subsequent doses.

Tailoring dose to achieve maximal effect is likely to result in biggest long-term reward.
What do we need to know?

Dose:
- Threshold (≈ 150 min/week)
- Frequency (3+ d/wk)
- Intensity/Duration (HIIT, sedentary time?)

Interactions with diet

Interactions with other medications
No-Exercise

LO = 3 bouts at 50% 
$VO_2_{max,}\,=\,750\,kcal$

HI = 3 bouts at 75% 
$VO_2_{max,}\,=\,750\,kcal$

Braun et al. J Appl. Physiol. 1995
Interactions with diet: Energy balance?

- Energy Deficit “DEF”
- Energy Balance “BAL”
- 16 men and women

Weight Maintenance Period

Pre-Training Insulin Action

6 DAYS OF EXERCISE

Post-Training Insulin Action
<table>
<thead>
<tr>
<th></th>
<th>DEF</th>
<th>BAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy Ingested (kcal)</td>
<td>2246 ± 97</td>
<td>2925 ± 159</td>
</tr>
<tr>
<td>Estimated Energy</td>
<td>2727 ± 182</td>
<td>2917 ± 169</td>
</tr>
<tr>
<td>Expenditure (kcal)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy Balance (kcal)</td>
<td>-481 ± 24</td>
<td>+8 ± 20</td>
</tr>
<tr>
<td>Weight Change (kg)</td>
<td>-0.62 ± 0.2</td>
<td>+0.03 ± 0.2</td>
</tr>
</tbody>
</table>

All food provided, EE derived from RMR, accelerometers, food, activity records
Whole-body and hepatic insulin action (CIG-SIT)

<table>
<thead>
<tr>
<th>90 min [6,6 $^2$H] glucose</th>
<th>Change infusate</th>
<th>60 min (20% glucose + 2% [6,6 $^2$H] glucose)</th>
</tr>
</thead>
</table>

Fasted state  
0  
75  
90  
Steady-state  
140  
145  
150

**Outcomes:** whole-body glucose uptake and suppression of liver glucose output
Black et al. J Appl Physiol, 2005

![Graph showing Rd (μM/kg FFM/min)/SS Ins comparison between DEF and BAL with Pre and Post conditions.](image)
Energy balance the only difference?

CHO content of diets in 2 groups different.

DEF = 330 g CHO/day; BAL = 410g/day.

Meal (60% CHO) immediately post-exercise
Weight loss leads to a beneficial impact on metabolic health through lifestyle changes and pharmacology. Exercise training and acute exercise have a timing effect on energy balance, which can be improved by meal CHO timing.
Diabetes Prevention Program, NEJM, 2001

Lifestyle + metformin = even better?
Exercise and metformin

**Purpose**: Combined effect of metformin and acute exercise on insulin sensitivity and AMPK α2

**Hypothesis**: $1 + 1 = 2$
Metformin group: 
pre-Met, Met + rest, post Met + Ex

Placebo group:
rest, exercise

<table>
<thead>
<tr>
<th>Overnight Fast</th>
<th>40 min rest or exercise</th>
<th>BIOPSY</th>
<th>90 min. stable isotope [6,6-2H] glucose infusion</th>
<th>euglycemic hyperinsulinemic clamp</th>
</tr>
</thead>
</table>

Percutaneous biopsy of vastus lateralis

Goodyear lab for analyses of AMPK activity, glycogen, and western blots.
Sharoff et al., Am J Phys, 2010
Does metformin blunt beneficial effects of training?

32 men and women with prediabetes

12 wks training with or w/o metformin, metformin only and control

Insulin sensitivity using clamp and tracers
Insulin sensitivity enhanced more with exercise alone than when combined with metformin.

* Malin et al. Diabetes Care, 2011
Non glycemic outcomes

**SBP:**
C = +6.5%, M = -7.3%, EP = -6.3%, EM = 0.0%

**hs-CRP:**
C = +6.4%, M = -20.1%, EP = -27.4%, EM = -8.4%

**TAG:**
C = +3.1% M = -13.8%, EP = -13.5%, EM = -12.0%
Why?

Wt? Only M and E+M lost weight
Fat? M = nc, E+M and E+P = -2%
Central fat? M = nc, E+M and E+P = -1.5%

CRF? M = nc, E+M ≈ +10%, E+P ≈ +20%

ΔVO2peak and Δinsulin sensitivity: \( r = .70 \)
Weight loss

Lifestyle change

exercise training

acute exercise

metformin

energy balance

meal CHO

timing

有益于代谢健康的影响
Role of “sedentary behavior” in mediating efficacy of the exercise drug??
14 normally active men and women
3 conditions, balanced order

Active, energy bal (no sit 15 hr.)

Inactive (sit 15 hr, no diet change)

Inactive, (sit 15 hr, cut kcals)
Sedentary subjects
Control, 12 wks training (EX), reduced sedentary time (rST) OR both (EX+rST).

EX+rST accentuated impact of EX alone
C-ISI up by 24% vs. 17.5% (but TG same)

Little impact of rST alone
Lifestyle change

exercise training

acute exercise

Weight loss

exercise training

energy balance

meal CHO

timing

beneficial impact on metabolic health

metformin
Conclusions

At sufficient dose, exercise/physical activity potent countermeasure

Less sedentary behavior useful but not sufficient

Interxns between exercise and nutritional context

Interactions with other meds NOT predictable
beneficial impact on metabolic health
Tara D’Eon, PhD
Steve Black PhD
Carrie Sharoff PhD
Brooke Stephens PhD
Kaila Holtz MS
Todd Hagobian PhD
Rebecca Hasson PhD
Steve Malin, PhD
Rob Gerber MS
Kirsten Thomson MS
Cameron Carter, MS
Rich Viskochil MS
Jen Blankenship, MS
Hannah Masse, BS
Patty Freedson, PhD
Stuart Chipkin MD
Laurie Goodyear PhD
John Staudenmayer PhD
Sarah Kozey Keadle, PhD
Kate Lyden, PhD

NIH 5 R56 DK081038
American Diabetes Assoc. 7-04-JF-10
Glass Charitable Trust
Baystate/UMass CBRP
ACSM Student grants